MCK: Biosimilar Co Manufacturing Will Shape Future Healthcare Safe Haven Appeal

Analysts have trimmed the McKesson fair value estimate by about $39 to $951.73. This reflects updated views on slightly higher discount rates, a more moderate revenue growth outlook, a small shift in profit margin assumptions, and a lower future P/E multiple after a mix of recent price target increases and cuts across the Street.

Analyst Commentary

Recent Street research on McKesson shows a split in tone, with some analysts focusing on upside from new business opportunities and others dialing back expectations and price targets. The result is a mixed but informative backdrop for assessing where the stock might fit in your portfolio construction.

Bullish Takeaways

Bullish analysts highlight the potential upside from McKesson's involvement with biosimilars, pointing to the new National Drug Code for a biosimilar version of Neulasta and the pipeline of seven large biosimilars over the next few years as an additional source of optionality for growth and earnings quality.
Some bullish views link this biosimilar exposure to potential co-manufacturing opportunities, which are being incorporated into higher valuation frameworks, including prior target moves that reflected extra value for these newer revenue streams.
One group of analysts expects the stock to remain appealing for investors looking for perceived safety within healthcare, even while acknowledging that McKesson trades at a premium to its three year average P/E multiple.
Earlier target increases from bullish analysts show that parts of the Street still see room for McKesson to execute on its growth initiatives while maintaining a valuation they consider justified by the business mix.

Bearish Takeaways

Bearish analysts have recently cut price targets on McKesson by varying amounts, which feeds into a lower blended future P/E assumption and signals more caution around how much investors should be willing to pay for the stock.
Some cautious views focus on the stock's premium of about 15% to its three year average P/E, raising questions about how much of the perceived safety and execution story is already reflected in the current valuation.
Additional target trims, including from major firms such as JPMorgan and BofA, point to a more measured stance on medium term growth and margin assumptions, even for analysts who had previously been more constructive.
The mix of cuts and smaller upward revisions suggests that execution risks and timing around newer initiatives, such as biosimilars, are being more heavily discounted in some models, which aligns with the lower fair value estimate cited earlier.

What's in the News

From January 1, 2026 to March 31, 2026, McKesson repurchased 2,500,000 shares, representing 2.03% of its shares, for US$2,695.61m, completing a total of 66,500,000 shares repurchased, or 43.79%, for US$21,125.49m under the buyback announced on May 24, 2018 (Key Developments).
On April 29, 2026, McKesson increased its equity buyback authorization by an additional US$5,000m, bringing the total authorization to US$29,000m (Key Developments).
McKesson announced that Executive Vice President and CFO Britt Vitalone will retire after a 20-year career with the company, and that Kenny Cheung, formerly Executive Vice President and CFO at Sysco, will join as CFO effective May 29, 2026. Vitalone will continue as a strategic advisor to support the transition and the planned separation of the Medical Surgical Solutions business (Key Developments).

Valuation Changes

Fair Value: trimmed from $990.87 to $951.73, a reduction of about 4% in the updated model.
Discount Rate: raised slightly from 6.98% to 7.11%, signaling a modest increase in required return assumptions.
Revenue Growth: lowered from 8.12% to 7.37%, reflecting a more moderate outlook for top line expansion.
Net Profit Margin: adjusted upward from 1.19% to 1.21%, indicating a small improvement in expected profitability.
Future P/E: reduced from 23.04x to 20.49x, pointing to a more conservative valuation multiple applied to future earnings.

2 views

Key Takeaways

Expansion into specialty pharmaceuticals and value-added services strengthens revenue quality, customer relationships, and recurring income streams.
Operational efficiency gains driven by automation and digitization support margin improvement and reinforce market leadership.
Regulatory pressures, industry consolidation, lower-margin generics, shifting healthcare access, and technology disruption all threaten McKesson's traditional revenue streams and long-term profit sustainability.

Catalysts

About McKesson

Provides healthcare services in the United States and internationally.What are the underlying business or industry changes driving this perspective?

Growing demand for pharmaceuticals and medical supplies, fueled by an aging population and higher chronic disease rates, underpins accelerating prescription volume growth, which supports sustained top-line revenue expansion for McKesson.
Increasing adoption of specialty and oncology pharmaceuticals, alongside recent acquisitions (Core Ventures and PRISM Vision) that expand the provider network and service portfolio, are improving revenue mix quality and positioning the company for higher operating margins and earnings growth.
Investments in digitization, automation, and advanced analytics across distribution centers and logistics (e.g., automated picking systems, AI, robotics) are enhancing operational efficiency, driving measurable reductions in operating expenses and supporting long-term net margin improvement.
Expanding value-added services, such as pharmacy management, patient access/adherence solutions, and commercialization support for biopharma customers, allow for stronger customer relationships, greater recurring revenue streams, and improved revenue visibility.
Increasing complexity of the pharmaceutical supply chain (e.g., biosimilars, cold chain logistics, personalized medicine) disproportionately benefits large, sophisticated distributors like McKesson, enabling competitive market share gains and enhanced supply chain resiliency, contributing to both top-line and margin expansion.

McKesson Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming McKesson's revenue will grow by 7.4% annually over the next 3 years.
Analysts are assuming McKesson's profit margins will remain the same at 1.2% over the next 3 years.
Analysts expect earnings to reach $6.1 billion (and earnings per share of $55.06) by about May 2029, up from $4.8 billion today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 20.6x on those 2029 earnings, up from 18.5x today. This future PE is lower than the current PE for the US Healthcare industry at 23.2x.
Analysts expect the number of shares outstanding to decline by 3.92% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.11%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Rising regulatory and governmental pressure on drug pricing and healthcare costs could compress McKesson's profit margins over the long term, as the company notes the dynamic and policy-driven environment and ongoing engagement with policymakers-potentially threatening both revenue growth and net margins.
Accelerating vertical integration and consolidation among drug manufacturers, payers, and pharmacy benefit managers (e.g., PBMs adopting in-sourcing strategies, "Caremark in-sourcing") may disintermediate traditional wholesalers, reducing McKesson's addressable market and putting sustained pressure on long-term revenues and operating profits.
Steady transition toward biosimilars and generics, which are highlighted as only "steady contributors" to earnings and usually deliver lower gross margins than branded drugs, may limit future profit opportunities and drag on overall net margin expansion over time.
Potential declines in healthcare access and rising uninsured rates (such as possible Medicaid cuts or "upward pressure on the uninsured rate") could negatively impact prescription and service volumes, ultimately reducing McKesson's long-term revenue base in its core wholesale business.
In the rapidly changing healthcare delivery ecosystem (including growth of digital-first and direct-to-consumer models), McKesson faces execution risk with slow adaptation to technological transformation-any lag in automation, digitization, or strategic innovation versus competitors could erode operating margins and earnings sustainability in the long run.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $951.73 for McKesson based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $1065.0, and the most bearish reporting a price target of just $812.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $499.3 billion, earnings will come to $6.1 billion, and it would be trading on a PE ratio of 20.6x, assuming you use a discount rate of 7.1%.
Given the current share price of $734.69, the analyst price target of $951.73 is 22.8% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on McKesson?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Analysts Boost McKesson Outlook Amid Strong Growth Guidance and Recent Valuation Adjustments